Prognostic significance of the gene-expression profile of breast cancer as determined with DNA-microarrays;Prognostische betekenis van het genexpressieprofiel van mammatumoren, bepaald met DNA-microarrays

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 12, 2005, Pages 638-646

  Van't Veer, L J ^a   Rodenhuis, S ^a   Van De Vijver, M J ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CLUSTER ANALYSIS; DNA FINGERPRINTING; DNA MICROARRAY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; PROGNOSIS; PROTEIN EXPRESSION; RELIABILITY; TUMOR VOLUME;

EID: 16244409807     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1452-67.
2. Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930-42.
3. Jansen SJ, Kievit J, Nooij MA, Haes JC de, Overpelt IM, Slooten H van, et al. Patients' preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile? Br J Cancer 2001;84: 1577-85.
4. Duric V, Stockler M. Patients' preferences for adjuvant chemotherapy in early breast cancer: a review of what makes it worthwhile. Lancet Oncol 2001;2:691-7.
5. Bontenbal M, Nortier JWR, Beex LVAM, Bakker P, Hupperets PSGJ, Nooij MA, et al. Adjuvante systemische therapic voor patiënten met resectabel mammacarcinoom; richtlijn van het Nationaal Borstkanker Overleg Nederland en de Nederlandse Vereniging voor Medische Oncologie. Ned Tijdschr Geneeskd 2000;144:984-9.
6. Bundred NJ. Prognostic and predictive factors in breast cancer. Cancer Treat Rev 2001;27:137-42.
7. Mohr S, Leikauf GD, Keith G, Rihn BH. Microarrays as cancer keys: an array of possibilities. J Clin Oncol 2002;20:3165-75.
8. Braam GB, Bluyssen HAR, Voest EE, Koomans HA. Genexpressie-analyse met behulp van DNA-microarrays. Ned Tijdschr Geneeskd 2002;140:1867-73.
9. Linn SC, Rijn M van de, Giaccone G. Toekomstige verfijning van diagnostiek en therapie met DNA-microarrays. I. Technologie en data-analyse. Ned Tijdschr Geneeskd 2003;147:795-9.
10. Linn SC, Rijn M van de, Giaccone G. Toekomstige verfijning van diagnostiek en therapie met DNA-microarrays. II. Toepassingen. Ned Tijdschr Geneeskd 2003;147:800-4.
11. Sauter G, Simon R. Predictive molecular pathology. N Engl J Med 2002;347:1995-6.
12. Perou CM, Sørlie T, Eisen MB, Rijn M van de, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-52.
13. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinghuish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001; 98:10869-74.
14. Veer LJ van 't, Dai H, Vijver MJ van de, He YD, Hart AAM, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
15. Vijver MJ van de, He YD, Veer LJ van 't, Dai H, Hart AAM, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
16. Bartelink H, Horiot JC, Poortmans P, Struikmans H, Bogaert W van den, Barillot I, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001;345:1378-87.
17. De Bono JS, Tolcher AW, Rowinsky EK. The future of cytotoxic therapy: selective cytotoxicity based on biology is the key. Breast Cancer Res 2003;5:154-9.
18. Sotiriou C, Powles TJ, Dowsett M, Jazaeri AA, Feldman AL, Assersohn L, et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res 2002;4:R3.
19. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003;362:362-9.